```
=> d his

     (FILE 'HOME' ENTERED AT 11:00:00 ON 18 DEC 2007)

     FILE 'REGISTRY' ENTERED AT 11:00:07 ON 18 DEC 2007
L1               STRUCTURE UPLOADED
L2             0 S L1
L3           127 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:00:39 ON 18 DEC 2007
L4            29 S L3
L5             2 S US200!-522225/APPS
L6             1 S L4 AND L5
L7            28 S L4 NOT L5

     FILE 'REGISTRY' ENTERED AT 11:01:03 ON 18 DEC 2007

     FILE 'CAPLUS' ENTERED AT 11:01:18 ON 18 DEC 2007

     FILE 'CAPLUS' ENTERED AT 11:18:59 ON 18 DEC 2007

     FILE 'REGISTRY' ENTERED AT 11:45:10 ON 18 DEC 2007
L8               STRUCTURE UPLOADED
L9             1 S L8 SAM SUB=L3
L10           17 S L8 SSS FULL SUB=L3

     FILE 'CAPLUS' ENTERED AT 11:45:39 ON 18 DEC 2007
L11            5 S L10
L12            4 S L10 NOT L6

     FILE 'REGISTRY' ENTERED AT 11:46:00 ON 18 DEC 2007

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> d l8
L8 HAS NO ANSWERS
L8                STR
```



Structure attributes must be viewed using STN Express query preparation.

C:\Program Files\Stnexp\Queries\10522225-elected-subgenus.str





chain nodes :
8 9 10 11 12 13
ring nodes :
1 2 3 4 5 6 14
chain bonds :
5-8 8-9 8-10 10-11 11-12 11-13 11-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
5-8 8-9 8-10 10-11 11-12 11-13 11-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:Atom

C:\Program Files\Stnexp\Queries\10522225-elected-species.str





chain nodes :
8 9 10 11 12 13
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19
chain bonds :
5-8 8-9 8-10 10-11 11-12 11-13 11-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
5-8 8-9 8-10 10-11 11-12 11-13 11-14 14-15 14-19 15-16 16-17 17-18 18-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 14 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

=> d l6 bib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:101114 CAPLUS
DN 140:163580
TI Preparation of (hetero)aryl ketones as 11βHSD1 inhibitors
IN Barton, Peter John; Clarke, David Stephen; Davies, Christopher Daniel; Hargreaves, Rodney Brian; Pease, Janet Elizabeth; Rankine, Maureen Theresa
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004011410	A1	20040205	WO 2003-GB3171	20030723
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2494668	A1	20040205	CA 2003-2494668	20030723
	AU 2003254481	A1	20040216	AU 2003-254481	20030723
	BR 2003012957	A	20050614	BR 2003-12957	20030723
	EP 1549600	A1	20050706	EP 2003-771150	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1681763	A	20051012	CN 2003-822440	20030723
	JP 2005533858	T	20051110	JP 2004-523925	20030723
	NO 2005000065	A	20050422	NO 2005-65	20050106
	ZA 2005000253	A	20051027	ZA 2005-253	20050111
	US 2005272036	A1	20051208	US 2005-522225	20050124 <--
	MX 2005PA01009	A	20050516	MX 2005-PA1009	20050125
PRAI	GB 2002-17433	A	20020727		
	GB 2002-30318	A	20021224		
	WO 2003-GB3171	W	20030723		

OS MARPAT 140:163580
GI



I

AB The title compds. [I; ring A = (hetero)aryl; R1 = halo, NO2, CN, etc.; n = 0-3; R2-R5 = H, OH, NH2, etc.; X, Z = O, CO, (un)substituted CH2, etc.; r = 1-2; q, p, s = 0-1; ring B = carbocyclyl, heterocyclyl; R6 = halo, NO2, CN, etc.; m = 0-3], useful in the inhibition of 11βHSD1, were prepared Thus, reacting 4-ClC6H4MgBr with N-methoxy-N-methyl-3-thienylmethanamide (preparation given) in THF afforded (thien-3-ylmethyl)(4-chlorophenyl)ketone. The compds. I typically show an IC50 < 10 μM against 11βHSD1. Pharmaceutical composition comprising the compound I is claimed.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:160843 CAPLUS Full-text
DN 142:261393
TI Preparation of 7-(1-pyrrolyl)-3,5-dihydroxyheptanoic acid derivatives as HMG-CoA reductase inhibitors
IN Kennedy, Robert Michael; Park, William Keun-Chan; Roth, Bruce David; Song, Yuntao; Trivedi, Bharat K.
PA Pfizer Inc., USA
SO U.S. Pat. Appl. Publ., 83 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005043364	A1	20050224	US 2004-862844	20040607
	US 7250444	B2	20070731		
PRAI	US 2003-494216P	P	20030611		

OS CASREACT 142:261393; MARPAT 142:261393
GI



I

II

AB The title compds. (I) or pharmaceutically acceptable salts, esters, amides, stereoisomers, or prodrugs thereof, or a pharmaceutically acceptable salts of the prodrug [wherein R2 = each (un)substituted benzyl, naphthyl, cyclohexyl, Ph, or pyridinyl, C1-7 alkyl; one of R3 and R4 = H, each (un)substituted aryl, aralkyl, heteroaryl, or heteroaralkyl, C1-8 alkyl straight chain or branched, or C3-6 cycloalkyl and the other one of R3 and R4 = iodo, COOR', R6R7NC(O)-, or SO2NR9R10; one of R6 and R7 = SO2NHR8 or SO2R8 and the other one of R6 and R7 is H or C1-4 alkyl; R8 = each (un)substituted aryl or heteroaryl; R9, R10 = independently H each (un)substituted aryl, aralkyl, heteroaryl, heteroaralkyl, or C1-10 alkyl; or N, R9 and R10 taken together form a (un)substituted 4-11 member ring optionally containing up to 2 heteroatoms selected from O, N and S; R5 (un)substituted C1-4 alkyl; R' = independently H, lower alkyl; n = 0-2] are prepared These compds. are HMG Co-A reductase inhibitor compds. useful as hypocholesterolemic and hypolipidemic compds. Thus, 1,2-bis(4-fluorophenyl)-5-methylhexane-1,4-dione was cyclocondensed with tert-Bu (3R,5R)-3,5-O-isopropylidene-7-amino-3,5-dihydroxyheptanoate in the presence of

trimethylacetic acid in heptane/toluene (9/1 mixture) under refluxing for 16 h followed by treatment with a mixture of aqueous 1 N HCl and methanol, lactonization with a mixture of concentrated HCl and toluene under refluxing for 5 h, and saponification with a mixture of aqueous 1 N and MeOH, to give 7-[2,3-bis(4-fluorophenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid sodium salt (II). The compds. I inhibited HMG Co-A reductase with IC50 of about <1,000 nM.

IT 845280-95-7P 845281-19-8P 845281-35-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 7-(1-pyrrolyl)-3,5-dihydroxyheptanoic acid derivs. as HMG-CoA reductase inhibitors, hypocholesterolemics, and hypolipidemics)

RN 845280-95-7 CAPLUS
CN Piperidine, 1-[[2-(4-fluorophenyl)-2-oxoethyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 845281-19-8 CAPLUS
CN Piperidine, 1-[(2-oxo-2-phenylethyl)sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 845281-35-8 CAPLUS
CN Piperidine, 1-[[2-(4-methylphenyl)-2-oxoethyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:141025 CAPLUS Full-text
DN 142:240304

TI Preparation of pyrrole derivatives as HMGCo-A reductase inhibitors
IN Kennedy, Robert Michael; Park, William Keun-Chan; Roth, Bruce David; Song, Yuntao; Trivedi, Bharat Kalidas
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005014539	A2	20050217	WO 2004-IB2540	20040730
	WO 2005014539	A3	20050512		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2534494	A1	20050217	CA 2004-2534494	20040730
	EP 1656132	A2	20060517	EP 2004-769110	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004013468	A	20061017	BR 2004-13468	20040730
	JP 2007502265	T	20070208	JP 2006-523069	20040730
	MX 2006PA01721	A	20060519	MX 2006-PA1721	20060210
	US 2006287378	A1	20061221	US 2006-389664	20060324
PRAI	US 2003-494216P	P	20030811		
	US 2004-563124P	P	20040416		
	WO 2004-IB2540	W	20040730		
	US 2004-600705P	P	20040811		
	US 2005-105288	A1	20050413		

OS CASREACT 142:240304; MARPAT 142:240304
GI



I



II

AB The title pyrrole derivs. I [wherein R2 = (un)substituted PhCH2, naphthyl, or cyclohexyl; R3 and R4 = independently H, aryl, aralkyl, etc.; R5 = alkyl], or pharmaceutically acceptable salts, esters, amides, stereoisomers, or prodrugs thereof are prepared as HMGCo-A reductase inhibitors. For example, the compound II•Na was prepared in a multi-step synthesis. Some of compds. I inhibited HMGCo-A reductase with IC50 of ≤10 nM in rat. I are useful as hypocholesterolemics and hypolipemic agents. Formulations containing I as an active ingredient were also described.

IT 845280-95-7P 845281-19-8P 845281-35-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrrole derivs. as HMGCo-A reductase inhibitors)

RN 845280-95-7 CAPLUS
CN Piperidine, 1-[[2-(4-fluorophenyl)-2-oxoethyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 845281-19-8 CAPLUS
CN Piperidine, 1-[(2-oxo-2-phenylethyl)sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 845281-35-8 CAPLUS
CN Piperidine, 1-[[2-(4-methylphenyl)-2-oxoethyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L1 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:736252 CAPLUS Full-text
DN 137:263031

TI Preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors

IN Eriksson, Anders; Lepistoe, Matti; Lundkvist, Michael; Munck Af Rosenschoeld, Magnus; Zlatoidsky, Pavol

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074767	A1	20020926	WO 2002-SE472	20020313
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2440630	A1	20020926	CA 2002-2440630	20020313
	AU 2002237626	A1	20021003	AU 2002-237626	20020313
	AU 2002237626	B2	20070517		
	EE 200300445	A	20031215	EE 2003-445	20020313
	EP 1370556	A1	20031217	EP 2002-704031	20020313
	EP 1370556	B1	20060719		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008104	A	20040302	BR 2002-8104	20020313
	CN 1509272	A	20040630	CN 2002-809788	20020313
	CN 1509286	A	20040630	CN 2002-809915	20020313
	CN 1509276	A	20040630	CN 2002-810093	20020313
	JP 2004527515	T	20040909	JP 2002-573776	20020313
	HU 2004000327	A2	20050128	HU 2004-327	20020313
	NZ 528106	A	20050324	NZ 2002-528106	20020313
	EP 1676846	A2	20060705	EP 2006-8158	20020313
	EP 1676846	A3	20060726		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 333454	T	20060815	AT 2002-704031	20020313
	RU 2288228	C2	20061127	RU 2003-127734	20020313
	ES 2267986	T3	20070316	ES 2002-2704031	20020313
	CN 1962641	A	20070516	CN 2006-10106152	20020313
	IN 2003MN00805	A	20050318	IN 2003-MN805	20030827
	ZA 2003006731	A	20041129	ZA 2003-6731	20030828
	ZA 2003006732	A	20041129	ZA 2003-6732	20030828
	ZA 2003006734	A	20041129	ZA 2003-6734	20030828
	ZA 2003006737	A	20041129	ZA 2003-6737	20030828
	MX 2003PA08191	A	20040129	MX 2003-PA8191	20030910
	NO 2003004045	A	20031110	NO 2003-4045	20030912
	US 2004127528	A1	20040701	US 2004-471900	20040114
	HK 1059932	A1	20061222	HK 2004-102796	20040421
PRAI	SE 2001-902	A	20010315		
	CN 2002-810093	A3	20020313		
	EP 2002-704031	A3	20020313		
	WO 2002-SE472	W	20020313		

OS MARPAT 137:263031

GI



I

II

AB The title compds. [I; X = NR1, O, S; Y1, Y2 = O, S; Z = SO, SO2; m = 1, 2; A = a bond, alkyl, haloalkyl, etc.; R1 = H, alkyl, haloalkyl; R2, R3 = H, halo, alkyl, etc.; R4 = H, halo, alkyl, haloalkyl; R5 = monocyclic, bicyclic or tricyclic group selected from (un)substituted cycloalkyl, aryl, heterocycloalkyl, heteroaryl], useful as metalloproteinase inhibitors, especially as inhibitors of MMP12, were prepared Thus, reacting 1-[4-(4-fluorophenyl)phenyl]piperazine and 2-(2,5-dioxo-4-imidazolidinyl)- 1-ethanesulfonyl chloride (preparation given) in the presence Et3N in CH2Cl2 afforded II.

IT 459818-94-1P 459818-95-2P 459819-00-2P
462127-17-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors)

RN 459818-94-1 CAPLUS

CN Piperidine, 4-[(5-chloro-2-pyridinyl)oxy]-1-[(2-oxo-2-phenylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 459818-95-2 CAPLUS

CN Piperidine, 4-[(5-chloro-2-pyridinyl)oxy]-1-[(2-(4-fluorophenyl)-2-oxoethyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 459819-00-2 CAPLUS

CN Benzamide, 4-[[[4-(4-fluorophenyl)-1-piperidinyl]sulfonyl]acetyl]- (9CI) (CA INDEX NAME)

RN 462127-17-9 CAPLUS

CN Benzamide, 4-[[[4-[(5-chloro-2-pyridinyl)oxy]-1-piperidinyl]sulfonyl]acetyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:736236 CAPLUS Full-text

DN 137:247696

TI Preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors

IN Eriksson, Anders; Lepistoe, Matti; Lundkvist, Michael; Munck Af Rosenschoeld, Magnus; Zlatoidsky, Pavol

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 300 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074750	A1	20020926	WO 2002-SE475	20020313
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

	CA 2440632	A1	20020926	CA 2002-2440632	20020313
	AU 2002237629	A1	20021003	AU 2002-237629	20020313
	EE 200300439	A	20031215	EE 2003-439	20020313
	EP 1370536	A1	20031217	EP 2002-704034	20020313
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008105	A	20040309	BR 2002-8105	20020313
	CN 1509275	A	20040630	CN 2002-810041	20020313
	HU 2004000206	A2	20040830	HU 2004-206	20020313
	JP 2004527511	T	20040909	JP 2002-573759	20020313
	EP 1676846	A2	20060705	EP 2006-8158	20020313
	EP 1676846	A3	20060726		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1962641	A	20070516	CN 2006-10106152	20020313
	IN 2003MN00800	A	20050318	IN 2003-MN800	20030827
	MX 2003PA08180	A	20031212	MX 2003-PA8180	20030910
	NO 2003004025	A	20031113	NO 2003-4025	20030911
	US 2004147573	A1	20040729	US 2003-471808	20030912
PRAI	SE 2001-902	A	20010315		
	SE 2001-903	A	20010315		
	CN 2002-810093	A3	20020313		
	EP 2002-704031	A3	20020313		
	WO 2002-SE475	W	20020313		

OS MARPAT 137:247696

GI



I II

AB The title compds. [I; X = NR1, O, S; B = C, CH, and is a point of attachment of one or more other functional groups or side chains; Y1, Y2 = O, S; R1 = H, alkyl, haloalkyl], useful in the treatment of a disease or condition mediated by one or more metalloproteinase enzymes (no biol. data), were prepared E.g., a 4-step synthesis of II, starting with 4-(4-chlorophenyl)benzaldehyde, was given.

IT 459819-94-1P 459819-95-2P 459819-00-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors)

RN 459818-94-1 CAPLUS

CN Piperidine, 4-[(5-chloro-2-pyridinyl)oxy]-1-[(2-oxo-2-phenylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 459818-95-2 CAPLUS
CN Piperidine, 4-[(5-chloro-2-pyridinyl)oxy]-1-[[2-(4-fluorophenyl)-2-oxoethyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 459819-00-2 CAPLUS
CN Benzamide, 4-[[[4-(4-fluorophenyl)-1-piperidinyl]sulfonyl]acetyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.55	395.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-25.74

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:46:38 ON 18 DEC 2007